© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Type II Inflammation
Dupixent Safe, Effective Up to Four Years in Adults With Moderate-to-Severe Atopic Dermatitis
May 09, 2022
Safe and effective long-term treatment is important for stable disease control in atopic dermatitis.
There Remains an Unmet Need for EoE Treatments That Provide Effective, Long-term Disease Control
May 05, 2022
Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.
Researchers Compare Correlation of Two PROMs With Type 2 Inflammatory Mediators
May 01, 2022
In patients with chronic rhinosinusitis with nasal polyps, the 12-item Patient Reported Outcomes in Chronic Rhinosinusitis had a stronger correlation with type 2 inflammatory biomarkers than a more widely used measure.
Caregivers Mitigate Asthma Risk by Identifying Triggers Across Different Places
April 12, 2022
Interviews with caregivers of children with asthma highlight the ways they identify and mitigate asthma triggers across different places, such as home, neighborhoods, and schools.
Biologics Hold Promise to Improve QoL for Patients With Chronic Rhinosinusitis With Nasal Polyps
April 11, 2022
The standard of care does not control chronic rhinosinusitis with nasal polyps for a third of patients, but approved biologics may improve quality of life (QoL).
Across 3 Disease States, Dupixent Rapidly Improves Symptoms
April 07, 2022
A therapy that rapidly demonstrates improvements in clinical outcomes may have a positive impact on medication adherence.
Identifying Disparities in Treatment and Quality of Care Team Relationships for Patients With Asthma
March 15, 2022
Research presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found minority patients with asthma perceived lower quality interactions with their care team, but did not find significant differences in the prescription of biologic medications across racial/ethnic groups.
A Setback for Fasenra As a Treatment Chronic Rhinosinusitis With Nasal Polyps
March 15, 2022
The FDA issued a complete response letter, so AstraZeneca’s monoclonal antibody won’t be joining Nucala and Dupixent as treatments for chronic rhinosinusitis with nasal polyps anytime soon.
Childhood Asthma is Better Controlled with Education
March 14, 2022
A meta-analysis finds that providing both parents and children with asthma with information about managing their disease can reduce emergency room visits and hospitalizations.
Chronic Rhinosinusitis and Type 2 Inflammation
March 14, 2022
A recently published review delves into the role that type 2 inflammation plays chronic rhinosinusitis and the evidence that agents that interfere with that inflammatory pathway could be used as treatments.